Discovery of hPANK Activators with Improved Pharmacological Properties
Tangallapally, R., Edwards, A., Subramanian, C., Sharma, L.K., Yun, M., White, S.W., Jackowski, S., Rock, C.O., Lee, R.E.To be published.
Experimental Data Snapshot
Starting Model: experimental
View more details
Macromolecule Content 
Entity ID: 1 | |||||
|---|---|---|---|---|---|
| Molecule | Chains | Sequence Length | Organism | Details | Image |
| Pantothenate kinase 3 | 380 | Homo sapiens | Mutation(s): 0  Gene Names: PANK3 EC: 2.7.1.33 | ![]() | |
UniProt & NIH Common Fund Data Resources | |||||
PHAROS:  Q9H999 GTEx:  ENSG00000120137  | |||||
Entity Groups | |||||
| Sequence Clusters | 30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity | ||||
| UniProt Group | Q9H999 | ||||
Sequence AnnotationsExpand | |||||
Reference Sequence | |||||
| Ligands 6 Unique | |||||
|---|---|---|---|---|---|
| ID | Chains | Name / Formula / InChI Key | 2D Diagram | 3D Interactions | |
| ANP Download:Ideal Coordinates CCD File | D [auth A] | PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER C10 H17 N6 O12 P3 PVKSNHVPLWYQGJ-KQYNXXCUSA-N | |||
| MZI (Subject of Investigation/LOI) Download:Ideal Coordinates CCD File | C [auth A] | 2-(4-{2-[4-(6-chloropyridazin-3-yl)piperazin-1-yl]-2-oxoethyl}anilino)-2-oxoethyl acetate C20 H22 Cl N5 O4 MASGWEOQCQKQCO-UHFFFAOYSA-N | |||
| EDO Download:Ideal Coordinates CCD File | E [auth A], F [auth A] | 1,2-ETHANEDIOL C2 H6 O2 LYCAIKOWRPUZTN-UHFFFAOYSA-N | |||
| ACT Download:Ideal Coordinates CCD File | B [auth A] | ACETATE ION C2 H3 O2 QTBSBXVTEAMEQO-UHFFFAOYSA-M | |||
| CL Download:Ideal Coordinates CCD File | G [auth A] | CHLORIDE ION Cl VEXZGXHMUGYJMC-UHFFFAOYSA-M | |||
| MG Download:Ideal Coordinates CCD File | H [auth A] | MAGNESIUM ION Mg JLVVSXFLKOJNIY-UHFFFAOYSA-N | |||
| Length ( Å ) | Angle ( ˚ ) |
|---|---|
| a = 97.907 | α = 90 |
| b = 97.907 | β = 90 |
| c = 68.907 | γ = 120 |
| Software Name | Purpose |
|---|---|
| PHENIX | refinement |
| HKL-2000 | data reduction |
| HKL-2000 | data scaling |
| PHASER | phasing |
| Funding Organization | Location | Grant Number |
|---|---|---|
| Not funded | -- |